<DOC>
	<DOCNO>NCT00766909</DOCNO>
	<brief_summary>Cyclosporine ( CsA ) Tacrolimus ( Tac ) immunosuppressive agent comprise cornerstone treatment among organ transplant recipient . Unfortunately diabetes known complication transplantation , yet underlie mechanism type diabetes still unresolved . A direct comparison diabetogenic effect CsA Tac , without interference corticosteroid treatment , yet investigate use hyperinsulinemic euglycemic glucose clamp technique , best method estimate insulin sensitivity . Randomized , investigator-blinded cross-over study carry , study 10 healthy subject 10 hemodialysis patient . Each participant receive treatment CsA , Tac placebo respectively random order . The result relevance choice monitor immunosuppressive regimen kidney transplant recipient well development well treatment modality diabetes .</brief_summary>
	<brief_title>Diabetogenicity Cyclosporine Tacrolimus</brief_title>
	<detailed_description>Background : Post-transplantation diabetes mellitus ( PTDM ) complication calcineurin inhibitor ( CI ) cyclosporine ( CsA ) Tacrolimus ( Tac ) , much controversy still exist regard mechanism lead disorder . Several study use intravenous ( IVGTT ) oral glucose tolerance test show CsA Tac tend reduce insulin release , corticosteroid increase insulin resistance . Decreased insulin secretion may result beta-cell toxicity , apoptosis inhibition calcineurin signal cessating insulin gene transcription . Comparing drug use IVGTT show long-term glucose metabolism significantly different two . Reviewing literature brings forth data observe high incidence PTDM Tac-treated recipient conflict . To knowledge , comparison diabetogenic effect CsA Tac , without concomitant corticosteroid , never investigate use gold standard estimate insulin sensitivity ; hyperinsulinemic euglycemic glucose clamp ( HEGC ) . Hypotheses : CsA Tac able induce diabetes , exert acute chronic effect pancreas beta-cell performance insulin sensitivity . The hypothesized effect investigate follow study : 1 . Acute effect 10 healthy subject undergo HEGC 2 . Chronic effect 10 pre-transplant uremic patient undergo HEGC Methods : The study randomize , double-blinded ( Study 1 ) investigator blind ( Study 2 ) cross-over design . Each study subject participates three experimental study day interval 4-6 week . A HEGC carry study day , treatment include CsA , Tac placebo respectively random order . Following overnight fast healthy subject / uremic patient arrive research laboratory , catheter implant arm blood sample infusion purpose . Pulse induction : Glucose 6 mg/kg/min infuse every 10 minute follow 9 minute pause . From 30 90 min blood drawn every minute insulin every 10th minute glucose measurement . First phase insulin secretion : After 120 minute glucose 0.3 g/kg ( maximally 25 g ) infuse 2 min catheter flush 50 ml isotonic saline . Insulin , glucose c-peptide measure minute interval . Insulin infusion/HEGC : 1.0 mU/kg/min insulin infusion initiate 165th minute blood glucose level keep 5.0 mmol/L , use variable infusion 20 % glucose dilution throughout follow 120 minute . The final 30 min clamp consider hyperinsulinaemic steady state period . Aside glucose , insulin endocrinological parameter , measurement drug concentration CaN also perform . Perspectives : The study expect give valuable insight diabetogenic effect CI , show whether CsA Tac comparable Diabetogenicity . The result relevance choice monitor immunosuppressive regimen kidney transplant recipient well development well treatment modality diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Healthy volunteer ( Study 1 ) : 1 . Men . 2 . Age 18 year 50 year . Upper limit +2 year approve main investigator . 3 . Normal OGTT ( 0 120 min test ) . 4 . Body mass index ( BMI ) 20 30 kg/m2 . Allowed variation 5 % upper low limit . 5 . Normal serum creatinine ionisized calcium . Allowed variation 20 % upper low limit normal value creatinine 5 % calcium . 6 . Normal urine stix 7 . Written consent participate . Hemodialysis Patients ( study 2 ) : 1 . Age 18 year 70 year . Upper limit +2 year approve main investigator . 2 . BMI &lt; 30 kg/m2 . Allowed variation 5 % upper limit . 3 . On waitinglist kidney transplant . 4 . Haemodialysis candidate . 5 . Anticonceptive treatment ( contraceptive pill/intrauterine device/patch/ring/ implant/injectable contraceptive ) patient fertile woman . 6 . Written consent participate . Healthy volunteer ( Study 1 ) : 1 . Anaemia haemoglobin level &lt; 7 mmol/L 2 . Participation clinical trial . 3 . Subjects adhere test condition . 4 . Anamnesis clinically significant disease , : liver disease kidney disease , neurological disease gastrointestinal disease haematological disease endocrine disease lung disease cardiac disease 5 . Drug alcohol abuse , would render subject unfit accord main investigator . 6 . Blood donation 1 month prior study day 7 . Patients establish allergy CI medical product , might pose risk participate study . 8 . Use prescription drug within one month prior study day , unless clinically insignificant accord main investigator . 9 . Smoking 8 hour prior study day 10 . Vigorous exercise 30 minute prior study day . Hemodialysis Patients ( study 2 ) : 1 . Peritoneal dialysis . 2 . Anaemia haemoglobin level &lt; 6 mmol/L . 3 . Participation clinical trial . 4 . Treatment corticosteroid , CsA Tac . 5 . Patients adhere test condition . 6 . Patients establish allergy CI medical product , might pose risk participate study . 7 . Drug alcohol abuse , would render subject unfit accord main investigator . 8 . Anamnesis current diabetes and/or intake antidiabetic medication . 9 . Malignancy . 10 . Uncontrolled infection . 11 . Uncontrolled hypertension . 12 . Smoking 8 hour prior study day . 13 . Vigorous exercise 30 minute prior study day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Insulin pulsatility</keyword>
	<keyword>Insulin secretion</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Calcineurin inhibitor</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Tacrolimus</keyword>
</DOC>